Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the ...

ZORYVE foam 0.3% shows significant efficacy for scalp and body psoriasis, with FDA review anticipated by May 2025. Arcutis Biotherapeutics, Inc. announced positive results from a pivotal Phase 3 ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...

Results showed that ZORYVE foam, used as a once-daily monotherapy, not only improved psoriasis symptoms but also provided rapid relief from itch, with noticeable effects within 24 hours of the first ...

Q1 2025 Management View CEO Frank Watanabe highlighted four key points for the quarter: strong commercial and R&D execution, confidence in sustained growth for 2025 and beyond, growing momentum in the ...

ZORYVE cream - a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor in a once-daily cream formulation, approved in the United States for the treatment of plaque psoriasis and atopic ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Results showed that ZORYVE foam, used as a once-daily monotherapy, not only improved psoriasis symptoms but also provided rapid relief from itch, with noticeable effects within 24 hours of the ...

U.S. demand for ZORYVE cream 0.3% in plaque psoriasis continues to grow, with over 425,000 prescriptions filled since launch by over 18,000 unique prescribers, reflecting the high levels of ...